EMPLOYMENT AGREEMENTEmployment Agreement • March 25th, 2008 • ImmunoCellular Therapeutics, Ltd. • Biological products, (no disgnostic substances) • California
This Employment Agreement (this “Agreement”) is made as of the 18th day of February, 2008, by and between ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Corporation”), and Dr. Manish Singh (hereinafter called “Executive”).
AGREEMENTAgreement • March 25th, 2008 • ImmunoCellular Therapeutics, Ltd. • Biological products, (no disgnostic substances) • California
This Agreement (“Agreement”), dated as of this 14th day of February, 2008, by and among ImmunoCellular Therapeutics, Ltd., a Delaware corporation with its principal office at 1999 Avenue of the Stars, 11th Floor, Los Angeles, California 90067 (“ICT”), Molecular Discoveries LLC, a New York limited liability company with its principal office at 551 Fifth Avenue, New York, New York 10176 (“MDC”) and, as to those matters specifically referring to her by her name, Dr. Cohava Gelber (“Gelber”), is entered into with reference to the following facts:
CONSULTING AGREEMENTConsulting Agreement • March 25th, 2008 • ImmunoCellular Therapeutics, Ltd. • Biological products, (no disgnostic substances) • California
This Consulting Agreement, dated as of February 14, 2008 (the “Agreement”) is entered into by and between ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Company”), and Dr. Cohava Gelber (“Consultant”) with reference to the following facts:
MEMORANDUM OF AGREEMENTMemorandum of Agreement • March 25th, 2008 • ImmunoCellular Therapeutics, Ltd. • Biological products, (no disgnostic substances) • California
This Memorandum of Agreement (“Memorandum”), dated as of this 21st day of November, 2007, by and between ImmunoCellular Therapeutics, Ltd., a Delaware corporation with its principal office at 1999 Avenue of the Stars, 11th Floor, Los Angeles, California 90067 (“ICT”), and Molecular Discoveries LLC, a New York limited liability company with its principal office at 551 Fifth Avenue, New York, New York 10176 (“MDC”), is intended to summarize the basic terms of a technology acquisition agreement between the parties hereto, which will be embodied in a subsequent and more comprehensive agreement (the “Final Agreement”) that will include not only the provisions of this Memorandum, but also certain other terms and conditions that are customarily included in technology acquisition arrangements. This Memorandum is entered into with reference to the following facts:
